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Abstract: A patient with macular edema secondary to a branch retinal vein occlusion (BRVO) 
was treated with intravenous injections of infliximab, an antitumor necrosis factor (TNF)-α 
antibody, for her rheumatoid arthritis (RA). Before the injection, the thickness of the right fovea, 
determined by optical coherent tomography, was 629 µm and the best-corrected visual acuity 
(BCVA) was 20/50. After eight injections of infliximab and 10 months after the first injection, 
her foveal thickness was decreased to 293 µm and the visual acuity improved to 20/20. There 
was no recurrence of macular edema during the infliximab injections. However, the infliximab 
injection was stopped because the patient developed pneumonia. Eight months after stopping 
the infliximab injection, her foveal thickness increased to 494 µm. To treat the RA, her ortho-
pedists began weekly subcutaneous injections of etanercept, a fusion protein of a section of 
the TNF receptor and immunoglobulin. Five months later, the foveal thickness had decreased 
to 260 µm, and the visual acuity remained at 20/25+. Because TNF-α is known to break down 
the blood–retinal barrier, the improvements in our case suggest that TNF-α plays a role in the 
pathogenesis of macular edema in some patients with BRVO.
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Introduction
Macular edema is one of the most common complications in eyes with branch retinal 
vein occlusion (BRVO) and a major cause of visual deterioration.1 In addition to 
macular grid laser photocoagulation,2 intravitreal injections of steroids,3 vitrectomy,4 
and intravitreal injection of off-label bevacizumab,5 a monoclonal antibody against 
human vascular endothelial growth factor (VEGF), have been used to treat macular 
edema.
Tumor necrosis factor (TNF)-α is known to play a major role in inflammation, 
and is used to treat rheumatoid arthritis (RA). Infliximab, a humanized monoclonal 
anti-TNF-α antibody, and etanercept, a dimeric fusion protein consisting of the extra-
cellular domain of TNF receptor II and the Fc region of human immunoglobulin, are 
approved and used clinically to treat patients with RA.6,7 TNF-α is known to break 
down the blood–retinal barrier,8 and neutrophils activated by TNF-α release elastase 
which causes damage to endothelial cells and an increase in microvascular permeability. 
There are reports that anti-TNF-α is effective in treating macular edema associated 
with uveitis9 and diabetic retinopathy.10
We report a case of macular edema secondary to BRVO in which the degree of 
macular edema decreased during anti-TNF-α treatment for RA, increased when the Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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anti-TNF-α treatment was stopped, then decreased again 
when the anti-TNF-α treatment was restarted.
Case report
A 59-year-old woman noticed a decrease in the vision of 
her right eye in early June 2006, and because she was being 
treated for RA in the Department of Orthopedics at Nagoya 
University Hospital, she was referred to the Department of 
Ophthalmology at the same institution on 30 June 2006. 
At that time, she was being treated with prednisolone 
5 mg/day, diclofenac sodium 75 mg/day, salazosulfapyridine 
1000 mg/day, and methotrexate 8 mg/week for her RA. Her 
best-corrected visual acuity (BCVA) was 20/40 OD, and 
macular edema due to a BRVO was detected. Her foveal 
thickness determined by optical coherent tomography (OCT; 
OCT2000 or Stratus, Carl Zeiss Meditec, Oberkochen, Ger-
many) was 679 µm.
After obtaining approval from The Nagoya University 
Hospital internal ethics review board and her informed con-
sent, she was treated with intravitreal bevacizumab (IVB) 
beginning on 07 August 2006. She was injected with IVB 
three times, and the foveal thickness after each injection was 
298, 317, and 237 µm, and the BCVA was 20/40, 20/40, and 
20/33, respectively. Although bevacizumab was effective in 
decreasing the macular edema, the decrease was transient. 
After the third injection, the patient refused further injections. 
Thus, the final bevacizumab injection was on November 14, 
2006, and she was followed up without any ophthalmologic 
treatment.
On 28 December 2006, the foveal thickness determined 
by OCT was 629 µm, and the BCVA was 20/50 (Figures 1A 
and 1B). Because the RA was not well controlled with the oral 
treatment listed above, intravenous injections of   infliximab 
150 mg were started by the orthopedists on March 29, 2007. 
After five infliximab injections, the foveal thickness decreased 
to 465 µm. After the sixth injection of infliximab 150 mg, the 
amount of infliximab was increased to 200 mg, and after the 
second injection of 200 mg infliximab on February 7, 2008, 
the foveal thickness in her right eye decreased to 314 µm, 
and her visual acuity was 20/25 (Figure 1C). There was no 
recurrence of macular edema during the infliximab injections, 
and her right foveal thickness was 309 µm and her BCVA was 
20/20 on September 26, 2008 (Figures 1D and 1E).
The infliximab injections were stopped on December 12, 
2008 because she developed pneumonia and had joint surgery. 
She did not return to our department until May 29, 2009, more 
than five months after her last infliximab injection. We found 
that the macular edema had recurred, and the foveal thick-
ness was 494 µm (Figures 2A and 2B). On June 5, 2009, her 
orthopedists started a 25 mg/week subcutaneous injection of 
etanercept to treat the RA. On July 3, 2009, about one month 
after the start of the etanercept injections, the foveal thick-
ness had decreased to 369 µm (Figure 2C) and, on October 
23, 2009, about five months after the start of the etanercept 
injections, the foveal thickness was 260 µm (Figures 2D and 
2E). Her BCVA in the right eye was 20/25 or better throughout 
the period of etanercept treatment.
Discussion
We report the findings in a patient whose macular edema 
regressed after infliximab injections, as a secondary effect 
to her treatment for RA, then recurred after stopping the 
injections. The macular edema regressed again following 
etanercept injections. The infliximab injections were started 
nine months after the onset of the BRVO, and etanercept 
injection was started three years after the onset. These   findings 
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Figure 1 Fundus photographs and OCT images of a patient with macular edema associated with a BRVO. The patient was treated with infliximab. A) Fundus photograph of 
the right eye before the infliximab injections. B) OCT image of the right eye before the infliximab injections. C) OCT image of the right eye 10 months after the first infliximab 
injection. D) OCT image of the right eye 19 months after the first infliximab injection. E) Changes of foveal thickness and visual acuity during the infliximab treatment.
Abbreviations: BrVO, branch retinal vein occlusion; OCT, optical coherence tomography.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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strongly suggest that these anti-TNF-α drugs were effective in 
reducing the degree of macular edema. However, the foveal 
thickness decreased gradually for more than six months 
after starting the infliximab, and more than three months 
after starting etanercept. In addition, when the infliximab 
was stopped for eight months, the macular edema recurred. 
These results suggest that repeated anti-TNF-α injections are 
needed to obtain the maximum effect, and the injections need 
to be continued to remain effective. Because the reduction of 
foveal thickness was transient, similar to anti-VEGF treat-
ment, it is suggested that there could have been a systemic 
process occurring that may have influenced this localized 
inflammatory process.
Both VEGF and TNF-α are known to break down the 
blood–retinal barrier,8 and there are some reports that 
anti-TNF-α treatment is effective against macular edema 
associated with uveitis.9 Additionally, Sfikakis et al reported 
that anti-TNF-α treatment was effective in four of six eyes 
with diabetic macular edema, but not for two eyes with an 
epiretinal membrane.10 There is still no evidence that the 
ocular level of TNF-α is increased in eyes with macular 
edema secondary to BRVO.11 However, because injections of 
steroids are effective in treating the macular edema second-
ary to BRVO,3 low-grade inflammation seems to play a role 
in the pathogenesis of chronic macular edema secondary to 
BRVO. Our findings suggest that TNF-α may also contribute 
to the macular edema.
Macrophages are found on the inner limiting membrane 
of eyes with macular edema,12 and TNF-α is known to 
activate macrophages and increase VEGF expression.13 In 
addition, there has been a report of a significant reduction 
of macrophages and VEGF in RA patients after anti-TNF-α 
treatment.14 These reports suggest that anti-TNF-α therapy 
resolve the macular edema not by decreasing vascular 
  permeability directly, but by decreasing the expression of 
VEGF and/or other proteins related to inflammation.
Conclusion
From the clinical course of our patient, we conclude that 
TNF-α plays a role in the pathogenesis of her chronic macular 
edema secondary to BRVO. These findings suggest that anti-
TNF-α should be considered for the treatment of macular 
edema secondary to BRVO.
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